VRDN as reported
Viridian Therapeutics, Inc. reported $71M of revenue over the trailing twelve months, +23220% on the year before. 10 reported series are charted on this page, each one as filed.
$71M
Revenue, trailing twelve months · to Q2 2026 · +23220% against the twelve months before
- Net Income
- −$387M
Net Income · +12% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$335M
Free Cash Flow · +8.2% year on year · trailing twelve months to Q2 2026
- Op Margin
- −54975%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $71M | +23220% | Q2 2026 |
| Net Income | −$387M | +12% | Q2 2026 |
| EPS | −$4.30 | n/a | Q3 2024 · 7 quarters behind |
| Gross Margin | 35% | n/a | Q4 2016 · 38 quarters behind |
| Op Margin | −54975% | n/a | Q2 2026 |
| Net Margin | −52596% | n/a | Q2 2026 |
| ROE | −56% | n/a | Q2 2026 |
| ROA | −43% | n/a | Q2 2026 |
| ROIC | 884% | n/a | Q3 2025 |
| Free Cash Flow | −$335M | +8.2% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Viridian Therapeutics, Inc. (VRDN) - Revenue & ProfitRevenue & ProfitViridian Therapeutics, Inc. (VRDN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com